An observational study in Chronic Hepatitis B and Alcoholic Hepatitis, sponsored by Beijing Municipal Administration of Hospitals. Completed at 1 site in China. Open to participants aged 30 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Beijing Municipal Administration of Hospitals · Observational
This is an observational, exploratory study designed to investigate the effect of different levels of alcohol consumption on plasma cell-free DNA (cfDNA) methylation profiles in participants with chronic hepatitis B. A total of 85 participants with chronic hepatitis B are planned to be enrolled and grouped according to their alcohol consumption status into a non-drinking group, a drinking group, and a group with alcoholic hepatitis associated with alcohol consumption. Approximately 16 mL of peripheral blood will be collected from each participant for cfDNA methylation analysis. Plasma cfDNA methylation profiles will be compared among participants with different levels of alcohol consumption to explore the effects of alcohol consumption on cfDNA methylation.
This observational, exploratory study aims to preliminarily investigate differences in plasma cell-free DNA (cfDNA) methylation profiles among participants with chronic hepatitis B according to their level of alcohol consumption. No clinical therapeutic intervention will be administered as part of the study.
A total of 85 participants with chronic hepatitis B are planned to be enrolled. Participants will be grouped according to their alcohol consumption status into a non-drinking group, a drinking group, and a group with alcoholic hepatitis associated with alcohol consumption.
Approximately 16 mL of peripheral blood will be collected from each participant in two tubes (8 mL per tube) for cfDNA methylation analysis. Plasma cfDNA methylation profiles will be compared among participants with different levels of alcohol consumption to evaluate the effects of alcohol consumption on cfDNA methylation.
In addition, differential cfDNA methylation sites will be analyzed in relation to pathways associated with hepatic metabolism, inflammation, and apoptosis to explore the potential molecular mechanisms through which alcohol consumption affects cfDNA methylation in chronic hepatitis B.
954 studies on the registry are indexed under Hepatitis B, Chronic; 147 are open to participants now.
This study's enrollment of 85 is below the median of 400 across 229 observational studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →Beijing Municipal Administration of Hospitals is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of participants with chronic hepatitis B. Participants are grouped according to alcohol consumption status into a non-drinking group, a drinking group, and a group that has developed alcoholic hepatitis associated with alcohol consumption.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with chronic hepatitis B who do not consume alcohol.
Participants with chronic hepatitis B who consume alcohol.
Other: Alcohol Consumption
Participants with chronic hepatitis B who have developed alcoholic hepatitis associated with alcohol consumption.
Other: Alcohol Consumption
Alcohol consumption status was assessed in participants with chronic hepatitis B. Participants were categorized according to their alcohol consumption status into a non-drinking group, a drinking group, and a group with alcoholic hepatitis associated with alcohol consumption.
Plasma cfDNA Methylation Levels
Plasma cell-free DNA (cfDNA) methylation levels will be measured and compared among participants with chronic hepatitis B with different alcohol consumption status and participants with alcoholic hepatitis.
Time frame: Day 1 (at the time of blood sample collection)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Municipal Administration of Hospitals